IN THE CLAIMS

This listing of claims will replace all prior versions, and listings, of claims in the application:

Claim 1 (currently amended): A 5,11-Dihydrodiaryl[b,e][1,4]oxazepine ~~derivatives~~ represented by the following ~~general~~ formula [I], ~~stereoisomers~~ a stereoisomer thereof, a pharmacologically acceptable ~~salts~~ salt thereof, ~~and hydrates or solvates~~ a hydrate thereof, or a solvate thereof:



[I]

wherein rings G, J and K each represent benzene ring or a nitrogen-containing aromatic ring; ~~R^1 to R^8~~ each of R^1, R^2, R^3, R^4, R^5, R^6, R^7, and R^8 may be the same or different from one another and they each represent a halogen atom or hydrogen atom, ~~R^9 to R^{13}~~ each of R^9, R^{10}, R^{11}, R^{12}, and R^{13} may be the same or different from one another and they each represent a

hydrogen atom, a halogen atom, cyano group, hydroxyl group, a lower alkyl group, a lower alkoxyl group, amino group or a lower alkylamino group or a lower acylated derivative of such a group, a lower dialkylamino group or a cycloalkylamino group, or R^9 and R^{10} or R^{10} and R^{11} together form ~~$-O(CH_2)nO-$~~ $-O(CH_2)_{n'}O-$ group wherein [[n]] n' is 1, 2 or 3; A represents CH_2, CHOH, CO or O; B represents CH_2, CHOH or CO; or A-B represents CH=CH, D represents CH_2, CH_2-CH_2 or CH_2-CH_2-CH_2 or B-D represents CH_2; X and Z are bonded together to form CH_2-CH_2 or CH_2-CH_2-CH_2 and, in this case, Y represents a hydrogen atom; or Y and Z are bonded together to form CH_2-CH_2-CH_2 or ~~CH_2-CH_2-CH_2-CH_2~~ CH_2-CH_2-CH_2-CH_2 and, in this case, X represents a hydrogen atom; and when X and Z, and Y and Z are not bonded together, X and Y each represent a hydrogen atom and Z represents a lower alkyl group;

provided that when any of ~~R^9 to R^{13}~~ R^9, R^{10}, R^{11}, R^{12}, and R^{13} represents a cyclic amino group of the following formula [E], ~~R^1 to R^8~~ each of R^1, R^2, R^3, R^4, R^5, R^6, R^7, and R^8 may be a halogen atom or hydrogen atom but when none of ~~R^9 to R^{13}~~ R^9, R^{10}, R^{11}, R^{12}, and R^{13} is a cyclic amino group of formula [E], one or two of ~~R^1 to R^8~~ R^1, R^2, R^3, R^4, R^5, R^6, R^7, and R represent a halogen atom and the others represent a hydrogen atom:



[E]

wherein n and m each represent 1 or 2, and W represents carbon atom, or nitrogen which may be substituted with a lower alkyl group, or oxygen, or sulfur atom.

Claim 2 (currently amended): The 5,11-dihydrodiaryl[b,e][1,4]oxazepine, ~~derivatives, stereoisomers~~ stereoisomer thereof, pharmacologically acceptable ~~salts~~ salt thereof, or ~~hydrates~~ hydrate thereof according to claim 1 wherein rings G and J are both benzene rings.

Claim 3 (currently amended): The 5,11-dihydrodiaryl[b,e][1,4]oxazepine, ~~derivatives, stereoisomers~~ stereoisomer thereof, pharmacologically acceptable ~~salts~~ salt thereof, or ~~hydrates~~ hydrate thereof according to claim 1 wherein either ring G or J is pyridine ring and the other is benzene ring.

Claim 4 (currently amended): The 5,11-dihydrodiaryl[b,e][1,4]oxazepine, ~~derivatives, stereoisomers~~ stereoisomer thereof, pharmacologically acceptable ~~salts~~ salt thereof, or ~~hydrates~~ hydrate thereof according to any one of claims 1 to 3 wherein ring K is benzene ring.

Claim 5 (currently amended): The 5,11-dihydrodiaryl[b,e][1,4]oxazepine, ~~derivatives, stereoisomers~~ stereoisomer thereof, pharmacologically acceptable ~~salts~~ salt thereof, or ~~hydrates~~ hydrate thereof according to any one of claims 1 to 3 wherein ring K is pyridine ring, pyrimidine ring, pyrazine ring or pyridazine ring.

Claim 6 (currently amended): The 5,11-dihydrodiaryl[b,e][1,4]oxazepine, ~~derivatives, stereoisomers~~ stereoisomer thereof, pharmacologically acceptable ~~salts~~ salt thereof, or ~~hydrates~~ hydrate thereof according to claim 1 wherein rings G, J and K are benzene rings.

Claim 7 (currently amended): The 5,11-dihydrodiaryl[b,e][1,4]oxazepine, ~~derivatives, stereoisomers~~ stereoisomer thereof, pharmacologically acceptable ~~salts~~ salt thereof, or ~~hydrates~~ hydrate thereof according to ~~any of claims 1 to 6~~ claim 1, wherein X and Z are bonded together to form CH_2-CH_2 or CH_2-CH_2-CH_2 and Y represents a hydrogen atom.

Claim 8 (currently amended): The 5,11-dihydrodiaryl[b,e][1,4]oxazepine, ~~derivatives, stereoisomers~~ stereoisomer thereof, pharmacologically acceptable ~~salts~~ salt thereof, or ~~hydrates~~ hydrate thereof according to ~~any of claims 1 to 6~~ claim 1, wherein Y and Z are bonded together to form CH_2-CH_2-CH_2 or CH_2-CH_2-CH_2-CH_2 and X represents a hydrogen atom.

Claim 9 (currently amended): The 5,11-dihydrodiaryl[b,e][1,4]oxazepine, ~~derivatives, stereoisomers~~ stereoisomer thereof, pharmacologically acceptable ~~salts~~ salt thereof, or ~~hydrates~~ hydrate thereof according to ~~any of claims 1 to 6~~ claim 1, wherein X and Y are each a hydrogen atom and Z represents a lower alkyl group.

Claim 10 (currently amended): The 5,11-dihydrodiaryl[b,e][1,4]oxazepine, ~~derivatives, stereoisomers~~ stereoisomer thereof, pharmacologically acceptable ~~salts~~ salt thereof, or ~~hydrates~~ hydrate thereof according to ~~any of claims 1 to 9~~ claim 1, wherein either or both of R^{10} and R^{11} are methoxyl group or R^{10} and R^{11} together form methylenedioxyl group, and R^9, R^{12} and R^{13} are each a hydrogen atom.

Claim 11 (currently amended): The 5,11-dihydrodiaryl[b,e][1,4]oxazepine, ~~derivatives, stereoisomers~~ stereoisomer thereof, pharmacologically acceptable ~~salts~~ salt

thereof, or ~~hydrates~~ hydrate thereof according to ~~any of claims 1 to 9~~ claim 1, wherein R^{11} is methoxyl group, and R^9, R^{10}, R^{12} and R^{13} are each a hydrogen atom.

Claim 12 (currently amended): The 5,11-dihydrodiaryl[b,e][1,4]oxazepine, ~~derivatives, stereoisomers~~ stereoisomer thereof, pharmacologically acceptable ~~salts~~ salt thereof, or ~~hydrates~~ hydrate thereof according to ~~any of claims 1 to 9~~ claim 1, wherein either R^{10} or R^{11} is amino group, a lower alkylamino group, a lower acylated derivative of such a group, a lower dialkylamino group or a cycloalkylamino group, and the other is a hydrogen atom.

Claim 13 (currently amended): The 5,11-dihydrodiaryl[b,e][1,4]oxazepine, ~~derivatives, stereoisomers~~ stereoisomer thereof, pharmacologically acceptable ~~salts~~ salt thereof, or ~~hydrates~~ hydrate thereof according to ~~any of claims 1 to 9~~ claim 1, wherein either R^{10} or R^{11} is a cyclic amino group represented by formula [E] and the other is a hydrogen atom.

Claim 14 (currently amended): The 5,11-dihydrodiaryl[b,e][1,4]oxazepine, ~~derivatives, stereoisomers~~ stereoisomer thereof, pharmacologically acceptable ~~salts~~ salt thereof, or ~~hydrates~~ hydrate thereof according to claim 13 wherein all of R^1 to R^8 are a hydrogen atom.

Claim 15 (currently amended): The 5,11-dihydrodiaryl[b,e][1,4]oxazepine, ~~derivatives, stereoisomers~~ stereoisomer thereof, pharmacologically acceptable ~~salts~~ salt thereof, or ~~hydrates~~ hydrate thereof according to ~~any of claims 1 to 13~~ claim 1, wherein one

of ~~R^1 to R^8~~ R^1, R^2, R^3, R^4, R^5, R^6, R^7, and R^8 is fluorine atom or chlorine atom and the other is a hydrogen atom.

Claim 16 (currently amended): The 5,11-dihydrodiaryl[b,e][1,4]oxazepine, ~~derivatives, stereoisomers~~ stereoisomer thereof, pharmacologically acceptable ~~salts~~ salt thereof, or ~~hydrates~~ hydrate thereof according to ~~any of claims 1 to 13~~ claim 1, wherein one of R^2, R^3, R^6 and R^7 is fluorine atom or chlorine atom and others are each a hydrogen atom.

Claim 17 (currently amended): The 5,11-dihydrodiaryl[b,e][1,4]oxazepine, ~~derivatives, stereoisomers~~ stereoisomer thereof, pharmacologically acceptable ~~salts~~ salt thereof, or ~~hydrates~~ hydrate thereof according to ~~any of claims 1 to 16~~ claim 1, wherein A and B-D are both CH_2.

Claim 18 (currently amended): The 5,11-dihydrodiaryl[b,e][1,4]oxazepine ~~derivatives~~, pharmacologically acceptable ~~salts~~ salt thereof, or ~~hydrates~~ hydrate thereof according to claim 7 wherein the carbon atom to which X is bonded has an absolute configuration of R.

Claim 19 (currently amended): The 5,11-dihydrodiaryl[b,e][1,4]oxazepine ~~derivatives~~, pharmacologically acceptable ~~salts~~ salt thereof, or ~~hydrates~~ hydrate thereof according to claim 7 wherein the carbon atom to which X is bonded has an absolute configuration of S.

Claim 20 (currently amended): The 5,11-dihydrodiaryl[b,e][1,4]oxazepine ~~derivatives~~, pharmacologically acceptable ~~salts~~ salt thereof, or ~~hydrates~~ hydrate thereof

according to claim 8 wherein the carbon atom to which Y is bonded has an absolute configuration of R.

Claim 21 (currently amended): The 5,11-dihydrodiaryl[b,e][1,4]oxazepine ~~derivatives~~, pharmacologically acceptable ~~salts~~ salt thereof, or ~~hydrates~~ hydrate thereof according to claim 8 wherein the carbon atom to which Y is bonded has an absolute configuration of S.

Claim 22 (currently amended): A pharmaceutical composition, which comprises ~~containing any of~~ at least one 5,11-dihydrodiaryl[b,e][1,4]oxazepine ~~derivatives~~, ~~stereoisomers~~ stereoisomer thereof, pharmacologically acceptable ~~salts~~ salt thereof, ~~and hydrates~~ or hydrate thereof according to ~~any of claims 1 to 5 and 7 to 21 as the active ingredient~~ claim 1 and at least one pharmaceutically acceptable carrier.

Claim 23 (currently amended): A pharmaceutical composition, which comprises ~~containing any of~~ at least one 5,11-dihydrodiaryl[b,e][1,4]oxazepine ~~derivatives~~, ~~stereoisomers~~ stereoisomer thereof, pharmacologically acceptable ~~salts~~ salt thereof, ~~and hydrates~~ or hydrate thereof according to claim 6 ~~as the active ingredient~~ and at least one pharmaceutically acceptable carrier.

Claim 24 (currently amended): A ~~pharmaceutical composition~~ method for treating ~~or preventing~~ a functional ~~diseases~~ disease of the digestive ~~tracts~~ tract, ~~containing any~~ said method comprising administering an effective amount of a 5,11-dihydrodiaryl[b,e][1,4]oxazepine ~~derivatives~~, ~~stereoisomers~~ a stereoisomer thereof, a

pharmacologically acceptable ~~salts~~ salt thereof ~~and hydrates~~ or a hydrate thereof according to ~~any of claims 1 to 21 as the active ingredient~~ claim 1 to a subject in need thereof.

Claim 25 (currently amended): The ~~pharmaceutical composition for treating or preventing the diseases~~ method according to claim 24, wherein ~~the~~ said functional ~~diseases~~ disease of the digestive ~~tracts are diseases~~ tract is a disease of gastrointestinal motor ~~functions~~ function.

Claim 26 (withdrawn-currently amended): A 5,11-Dihydrodiaryl[b,e][1,4]oxazepine ~~derivatives~~ represented by the following ~~general~~ formula [XV], a stereoisomer ~~stereoisomers~~ thereof, ~~and salts~~ or a salt thereof:



[XV]

wherein rings G, J and K each represent benzene ring or a nitrogen-containing aromatic ring; ~~R^1 to R^8~~ each of R^1, R^2, R^3, R^4, R^5, R^6, R^7, and R^8 may be the same or different from one another and they each represent a halogen atom or a hydrogen atom, ~~R^9 to R^{13}~~ each of R^9,

R^{10}, R^{11}, R^{12}, and R^{13} may be the same or different from one another and they each represent a hydrogen atom, a halogen atom, cyano group, hy6droxyl group, a lower alkyl group, a lower alkoxyl group, amino group or a lower alkylamino group or a lower acylated derivative of such a group, a lower dialkylamino group or a cycloalkylamino group, or R^9 and R^{10} or R^{10} and R^{11} together form ~~$-O(CH_2)nO-$~~ $-O(CH_2)_{n'}O-$ group wherein [[n]] n' is 1, 2 or 3; L_1 represents CH_2, CHOH or O; L_2 represents CH_2, CHOH, CH_2-CH_2, CHOH-CH_2, CH_2-CH_2-CH_2 or CHOH-CH_2-CH_2; or L_1 and L_2 are bonded together to form CH_2, CHOH or CH=CH, Y and Z are bonded together to form CH_2-CH_2-CH_2 or CH_2-CH_2-CH_2-CH_2 or when Y and Z are not bonded together, Y represents a hydrogen atom and Z represents a lower alkyl group;

provided that when any of ~~R^9 to R^{13}~~ R^9, R^{10}, R^{11}, R^{12}, and R^{13} represents a cyclic amino group of the following formula [E], ~~R^1 to R^8~~ each of R^1, R^2, R^3, R^4, R^5, R^6, R^7, and R^8 may be a halogen atom or hydrogen atom but when none of ~~R^9 to R^{13}~~ R^9, R^{10}, R^{11}, R^{12}, and R^{13} is a cyclic amino group of formula [E], one or two of ~~R^1 to R^8~~ R^1, R^2, R^3, R^4, R^5, R^6, R^7, and R^8 represent a halogen atom and the others represent a hydrogen atom:



[E]

wherein n and m each represent 1 or 2, and W represents carbon atom, or nitrogen which may be substituted with a lower alkyl group, or oxygen, or sulfur atom.

Claim 27 (withdrawn-currently amended): An amide ~~Amide derivatives~~ of ~~general formulae~~ formula [XVI], ~~stereoisomers~~ a stereosiomer thereof, ~~and salts~~ or a salt thereof:



[XVI]

wherein rings G, J and K each represent benzene ring or a nitrogen-containing aromatic ring; ~~R^1 to R^8~~ each of R^1, R^2, R^3, R^4, R^5, R^6, R^7, and R^8 may be the same or different from one another and they each represent a halogen atom or hydrogen atom, ~~R^9 to R^{13}~~ each of R^9, R^{10}, R^{11}, R^{12}, and R^{13} may be the same or different from one another and they each represent a hydrogen atom, a halogen atom, cyano group, hydroxyl group, a lower alkyl group, a lower alkoxyl group, amino group or a lower alkylamino group or a lower acylated derivative of such a group, a lower dialkylamino group or a cycloalkylamino group, or R^9 and R^{10} or R^{10} and R^{11} together form ~~-O(CH$_2$)nO-~~ -O$(CH_2)_{n'}$O- group wherein [[n]] n' is 1, 2 or 3; L_1 represents CH_2, CHOH or O; L_2 represents CH_2, CHOH, CH_2-CH_2, CHOH-CH_2, CH_2-CH_2-CH_2 or CHOH-CH_2-CH_2; or L_1 and L_2 are bonded together to form CH_2, CHOH or CH=CH,

Y and Z are bonded together to form CH_2-CH_2-CH_2 or CH_2-CH_2-CH_2-CH_2 or when Y and Z are not bonded together, Y represents a hydrogen atom and Z represents a lower alkyl group; provided that when any of ~~R^9 to R^{13}~~ R^9, R^{10}, R^{11}, R^{12}, and R^{13} represents a cyclic amino group of the following formula [E], ~~R^1 to R^8~~ each of R^1, R^2, R^3, R^4, R^5, R^6, R^7, and R^8 may be a halogen atom or hydrogen atom but when none of ~~R^9 to R^{13}~~ each of R^9, R^{10}, R^{11}, R^{12}, and R^{13} is a cyclic amino group of formula [E], one or two of ~~R^1 to R^8~~ R^1, R^2, R^3, R^4, R^5, R^6, R^7, and R^8 represent a halogen atom and the others represent a hydrogen atom:



[E]

wherein n and m each represent 1 or 2, and W represents carbon atom, or nitrogen which may be substituted with a lower alkyl group, or oxygen, or sulfur atom.

Claim 28 (withdrawn-currently amended): The 5,11-dihydrodiaryl[b,e][1,4]oxazepine ~~derivatives~~, ~~stereoisomers~~ stereoisomer thereof, ~~and salts~~ or salt thereof according to claim 26, wherein ~~R^1 to R^8~~ each of R^1, R^2, R^3, R^4, R^5, R^6, R^7, and R^8 may be the same or different from one another and they each represent fluorine atom, chlorine atom or a hydrogen atom, L_1-L_2 represents CH_2 or CH_2-CH_2, Y and Z are bonded together to form CH_2-CH_2-CH_2 or CH_2-CH_2-CH_2-CH_2.

Claim 29 (withdrawn-currently amended): The 5,11-dihydrodiaryl[b,e][1,4]oxazepine ~~derivatives, stereoisomers and salts~~ stereoisomer thereof, or salt thereof according to claim 28 wherein rings G, J and K are benzene rings.

Claim 30 (withdrawn-currently amended): The amide ~~derivatives, stereoisomers~~ stereoisomer thereof, ~~and salts~~ or salt thereof according to claim 27, wherein ~~R^1 to R^8~~ each of R^1, R^2, R^3, R^4, R^5, R^6, R^7, and R^8 may be the same or different from one another and they each represent fluorine atom, chlorine atom or a hydrogen atom, L_1-L_2 represents CH_2 or CH_2-CH_2 and Y and Z are bonded together to form CH_2-CH_2-CH_2 or CH_2-CH_2-CH_2-CH_2.

Claim 31 (withdrawn-currently amended): The amide ~~derivatives, stereoisomers and salts~~ stereoisomer thereof, or salt thereof according to claim 30 wherein rings G, J and K are benzene rings.

Claim 32 (withdrawn-currently amended): The 5,11-dihydrodiaryl[b,e][1,4]oxazepine ~~derivatives, stereoisomers and salts~~ stereoisomer thereof, or salt thereof according to claim 29, wherein ~~R^9 to R^{13}~~ each of R^9, R^{10}, R^{11}, R^{12}, and R^{13} may be the same or different from one another and they each represent a hydrogen atom, amino group or a lower alkylamino group or a lower acylated derivative of such a group, a lower dialkylamino group or a cycloalkylamino group.

Claim 33 (withdrawn-currently amended): The amide ~~derivatives, stereoisomers and salts~~ stereoisomer thereof, or salt thereof according to claim 31, wherein ~~R^9 to R^{13}~~ each of R^9, R^{10}, R^{11}, R^{12}, and R^{13} may be the same or different from one another and they each

represent a hydrogen atom, amino group or a lower alkylamino group or a lower acylated derivative of such a group, a lower dialkylamino group or a cycloalkylamino group.

Claim 34 (withdrawn-currently amended): (R)-{[2-(3-Chloro-5,11-dihydrodibenzo[b,e][1,4]oxazepine-5-carbonyl)pyrrolidine]-1-yl}-2-(4-dimethylaminophenyl)ethanone, ~~and stereoisomers and salts~~ a stereoisomer thereof, or a salt thereof.

Claim 35 (withdrawn-currently amended): (R)-1-[(4-Dimethylaminophenyl)acetyl]pyrrolidine-2-carboxylic acid [2-(2-bromo-4-chlorobenzyloxy)phenyl]amide, ~~and stereoisomers and salts~~ a stereoisomer thereof, or a salt thereof.

Claim 36 (withdrawn-currently amended): (R)-{[2-(2-Fluoro-5,11-dihydrodibenzo[b,e][1,4]oxazepine-5-carbonyl)pyrrolidine]-1-yl}-2-(4-pyrrolidinophenyl)ethanone, ~~and stereoisomers and salts~~ a stereoisomer thereof, or a salt thereof.

Claim 37 (withdrawn-currently amended): (R)-1-[(4-Pyrrolidinophenyl)acetyl]pyrrolidine-2-carboxylic acid [2-(2-bromo-5-fluorobenzyloxy)phenyl]amide, ~~and stereoisomers and salts~~ a stereoisomer thereof, or a salt thereof.